The Ubiquitous Existence of MicroRNA in Body Fluids

Wang, Kai

doi:10.1373/clinchem.2016.267625

Cited by 23 publications

(19 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In experimental models the cluster induces cardiac hypertrophy, a risk factor for the transition to HF, through direct regulation of transcription factor FoxO3 expression and by interacting with angiotensin II signalling . Non‐coding regulatory RNAs, including miRNAs, may be released into the extracellular space and so they can be found in almost all body fluids . Several circulating miRNAs have been described as potential biomarkers for diagnosis, monitoring response to therapy, and for prognostic purposes in cardiovascular pathologies, including acute and chronic HF .…”

Section: Discussionmentioning

confidence: 99%

Circulating microRNA‐132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure

Masson

Bátkai

Beermann

et al. 2017

European J of Heart Fail

View full text Add to dashboard Cite

Aims Non‐coding microRNAs (miRNAs) are critically involved in cardiovascular pathophysiology. Since they are measurable in most body fluids, they have been proposed as circulating biomarkers. We examined the prognostic value of a specific candidate miRNA in a large cohort of patients with chronic heart failure (HF) enrolled in a multicentre clinical trial. Methods and results Plasma levels of miR‐132 were measured using miRNA‐specific PCR‐based technologies at randomization in 953 patients with chronic, symptomatic HF from the GISSI‐Heart Failure trial. The association with fatal (all‐cause and cardiovascular death) and non‐fatal events (time to first admission to hospital for cardiovascular reasons or worsening of HF) and the incremental risk prediction were estimated in adjusted models. Higher circulating miR‐132 levels were independently associated with younger age, better renal filtration, ischaemic aetiology of HF, more severe HF symptoms, higher diastolic blood pressure, higher cholesterol, and male sex. After extensive adjustment for demographic, clinical, and echocardiographic risk factors and baseline NT‐proBNP concentrations, miR‐132 remained associated only with HF hospitalizations (hazard ratio 0.79, 95% confidence interval 0.66–0.95, P = 0.01) and improved its risk prediction with the continuous net reclassification index (cNRI 0.205, P = 0.001). Conclusion In well characterized patients with chronic HF, circulating miR‐132 levels rise with the severity of HF. Lower circulating miR‐132 levels improved risk prediction for HF readmission beyond traditional risk factors, but not for mortality. MiR‐132 may be helpful to intensify strategies aimed at reducing re‐hospitalization, which has a substantial health and economic burden in HF.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating microRNA‐132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure

Masson

Bátkai

Beermann

et al. 2017

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…Comprehensive reviews on miRNAs involved in osteoblastogenesis and osteoclastogenesis, chondrogenesis and cartilage degradation, synovial inflammation and neurogenesis can be found elsewhere [15][16][17]. miRNAs can be found intracellularly or extracellularly, circulating in virtually any biological fluid in a remarkably stable manner [18][19][20]. Because biological fluids are generally obtainable through minimally invasive techniques, circulating miRNAs are attractive candidates for disease diagnosis, monitoring and prognostication [21,22].…”

Section: Introductionmentioning

confidence: 99%

Equine synovial fluid small non-coding RNA signatures in early osteoarthritis

et al. 2021

View full text Add to dashboard Cite

Background Osteoarthritis remains one of the greatest causes of morbidity and mortality in the equine population. The inability to detect pre-clinical changes in osteoarthritis has been a significant impediment to the development of effective therapies against this disease. Synovial fluid represents a potential source of disease-specific small non-coding RNAs (sncRNAs) that could aid in the understanding of the pathogenesis of osteoarthritis. We hypothesised that early stages of osteoarthritis would alter the expression of sncRNAs, facilitating the understanding of the underlying pathogenesis and potentially provide early biomarkers. Methods Small RNA sequencing was performed using synovial fluid from the metacarpophalangeal joints of both control and early osteoarthritic horses. A group of differentially expressed sncRNAs was selected for further validation through qRT-PCR using an independent cohort of synovial fluid samples from control and early osteoarthritic horses. Bioinformatic analysis was performed in order to identify putative targets of the differentially expressed microRNAs and to explore potential associations with specific biological processes. Results Results revealed 22 differentially expressed sncRNAs including 13 microRNAs; miR-10a, miR-223, let7a, miR-99a, miR-23b, miR-378, miR-143 (and six novel microRNAs), four small nuclear RNAs; U2, U5, U11, U12, three small nucleolar RNAs; U13, snoR38, snord96, and one small cajal body-specific RNA; scarna3. Five sncRNAs were validated; miR-223 was significantly reduced in early osteoarthritis and miR-23b, let-7a-2, snord96A and snord13 were significantly upregulated. Significant cellular actions deduced by the differentially expressed microRNAs included apoptosis (P < 0.0003), necrosis (P < 0.0009), autophagy (P < 0.0007) and inflammation (P < 0.00001). A conservatively filtered list of 57 messenger RNA targets was obtained; the top biological processes associated were regulation of cell population proliferation (P < 0.000001), cellular response to chemical stimulus (P < 0.000001) and cell surface receptor signalling pathway (P < 0.000001). Conclusions Synovial fluid sncRNAs may be used as molecular biomarkers for early disease in equine osteoarthritic joints. The biological processes they regulate may play an important role in understanding early osteoarthritis pathogenesis. Characterising these dynamic molecular changes could provide novel insights on the process and mechanism of early osteoarthritis development and is critical for the development of new therapeutic approaches.

show abstract

“…[5]. Due to their outstanding stability in the body fluids (plasma, serum, urine) of cancer patients, miRNAs have been heavily investigated over the years and proposed as the novel, minimally invasive, optimized biomarkers for the early diagnosis of various malignancies, including prostate cancer [6,7,8].…”

Section: Introductionmentioning

confidence: 99%

Biomarker Potential of Plasma MicroRNA-150-5p in Prostate Cancer

et al. 2019

View full text Add to dashboard Cite

Background and Objectives: Over decades, prostate cancer (PCa) has become one of the leading causes of cancer mortality in men. Extensive evidence exists that microRNAs (miRNAs or miRs) are key players in PCa and a new class of non-invasive cancer biomarkers. Materials and Methods: We performed miRNA profiling in plasma and tissues of PCa patients and attempted the validation of candidate individual miRs as biomarkers. Results: The comparison of tissue and plasma profiling results revealed five commonly dysregulated miRs, namely, miR-130a-3p, miR-145-5p, miR-148a-3p, miR-150-5p, and miR-365a-3p, of which only three show concordant changes—miR-130a-3p and miR-150-5p were downregulated and miR-148a-3p was upregulated in both tissue and plasma samples, respectively. MiR-150-5p was validated as significantly downregulated in both plasma and tissue cancer samples, with a fold change of −2.697 (p < 0.001), and −1.693 (p = 0.035), respectively. ROC analysis showed an area under the curve (AUC) of 0.817 (95% CI: 0.680–0.995) for plasma samples and 0.809 (95% CI: 0.616–1.001) for tissue samples. Conclusions: We provide data indicating that miR-150-5p plasma variations in PCa patients are associated with concordant changes in prostate cancer tissues; however, given the heterogeneous nature of previous findings of miR-150-5p expression in PCa cells, additional future studies of a larger sample size are warranted in order to confirm the biomarker potential and role of miRNA-150-5p in PCa biology.

show abstract

The Ubiquitous Existence of MicroRNA in Body Fluids

Cited by 23 publications

References 6 publications

Circulating microRNA‐132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure

Circulating microRNA‐132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure

Equine synovial fluid small non-coding RNA signatures in early osteoarthritis

Biomarker Potential of Plasma MicroRNA-150-5p in Prostate Cancer

Contact Info

Product

Resources

About